We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.9B
1-Year Est. Return 121.13%
This Fund
S&P 500
This Quarter Est. Return
+63.92%
1 Year Est. Return
+121.13%
3 Year Est. Return
+281.43%
5 Year Est. Return
+350.91%
10 Year Est. Return
–
AUM
$1.45B
AUM Growth
+$364M
Cap. Flow
+$152M
Cap. Flow %
10.45%
Top 10 Hldgs %
51.41%
Holding
99
New
31
Increased
26
Reduced
24
Closed
13

Top Buys

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$65.2M
2
ABVX
Abivax
ABVX
+$26.1M
3
QURE icon
uniQure
QURE
+$15.9M
4
DHR icon
Danaher
DHR
+$15.1M
5
PODD icon
Insulet
PODD
+$14.3M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$43.8M
2
INSP icon
Inspire Medical Systems
INSP
+$21.3M
3
IQV icon
IQVIA
IQV
+$15.4M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$15.3M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 89.94%
2 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QQQ icon
1
PUT
Invesco QQQ Trust
QQQ
$455B
$138M 9.52%
230,000
+57,800
+34% +$33.1M
UTHR icon
2
United Therapeutics
UTHR
$26.3B
$106M 7.32%
253,220
+193,854
+327% +$65.2M
GSK icon
3
GSK
GSK
$103B
$91.5M 6.31%
2,120,446
-121,942
-5% -$4.76M
NTRA icon
4
Natera
NTRA
$37.5B
$83.6M 5.76%
519,644
-276,731
-35% -$43.8M
VERA icon
5
Vera Therapeutics
VERA
$2.54B
$81.6M 5.62%
2,807,836
+424,781
+18% +$9.82M
SNDX icon
6
Syndax Pharmaceuticals
SNDX
$1.84B
$53.3M 3.68%
3,467,314
-598,041
-15% -$7.83M
PCVX icon
7
Vaxcyte
PCVX
$7.89B
$51.2M 3.53%
1,421,983
+123,469
+10% +$4.09M
QURE icon
8
uniQure
QURE
$2.68B
$51.2M 3.53%
+877,373
New +$15.9M
HCA icon
9
HCA Healthcare
HCA
$84.8B
$47.6M 3.28%
111,700
+11,717
+12% +$4.54M
VRDN icon
10
Viridian Therapeutics
VRDN
$2.13B
$41.5M 2.86%
1,924,306
+21,767
+1% +$393K
ZIMV
11
DELISTED
ZimVie
ZIMV
$39.4M 2.71%
2,079,380
– –
ABVX
12
Abivax
ABVX
$11B
$36.2M 2.5%
+426,499
New +$26.1M
IONS icon
13
Ionis Pharmaceuticals
IONS
$9.35B
$35.2M 2.43%
538,661
-50,239
-9% -$2.45M
RVTY icon
14
Revvity
RVTY
$12.3B
$34.6M 2.38%
394,311
-116,019
-23% -$10.5M
TVTX icon
15
Travere Therapeutics
TVTX
$5.33B
$33.9M 2.33%
1,417,204
+102,171
+8% +$1.92M
TECH icon
16
Bio-Techne
TECH
$11.2B
$32.9M 2.27%
591,540
+197,401
+50% +$10.6M
CLDX icon
17
Celldex Therapeutics
CLDX
$2.77B
$29.9M 2.06%
1,153,920
+315,184
+38% +$7.3M
TEVA icon
18
Teva Pharmaceuticals
TEVA
$35.9B
$27.5M 1.9%
1,363,653
+310,772
+30% +$5.46M
BRKR icon
19
Bruker
BRKR
$9.2B
$22.3M 1.54%
687,129
-152,155
-18% -$5.42M
CYH icon
20
Community Health Systems
CYH
$385M
$22.3M 1.54%
6,950,051
+805,667
+13% +$2.42M
UNH icon
21
UnitedHealth
UNH
$382B
$21.7M 1.5%
62,820
+2,084
+3% +$630K
DHR icon
22
Danaher
DHR
$135B
$19.7M 1.36%
99,273
+75,824
+323% +$15.1M
GERN icon
23
Geron
GERN
$911M
$17.3M 1.19%
12,599,002
+5,278,828
+72% +$7.03M
ELV icon
24
Elevance Health
ELV
$81.9B
$14.5M 1%
44,980
+26,018
+137% +$8.09M
PODD icon
25
Insulet
PODD
$11.3B
$14.1M 0.97%
+45,604
New +$14.3M
1
2 3 4

Similar funds

DCP
Distillate Capital Partners Chicago, Illinois $1.9B AUM 2.22% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $1.89B AUM 14.55% 1-Year Est. Return
OPCM
Osborne Partners Capital Management San Francisco, California $1.89B AUM 16.21% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
RCA
Resonant Capital Advisors Madison, Wisconsin $1.9B AUM 14.38% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $1.91B AUM 24.91% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
TF
Trek Financial Scottsdale, Arizona $1.88B AUM 41.21% 1-Year Est. Return

Eversept Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Eversept Partners held 99 positions worth $1.45B, up 33% from $1.09B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Eversept Partners deployed $152M of net new capital in Q3 2025, opening 31 new positions and adding to 26 existing holdings. Its largest new stake was Abivax: 426,499 shares worth $36.2M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 91% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Natera, an estimated $43.8M trimmed.

  • Eversept Partners's largest Q3 2025 buy was Abivax: 426,499 shares worth $36.2M.
  • Eversept Partners added most to United Therapeutics in Q3 2025, an estimated $65.2M increase.
  • Eversept Partners's biggest Q3 2025 reduction was Natera, cutting an estimated $43.8M.
  • Eversept Partners fully exited Inspire Medical Systems in Q3 2025, selling an estimated $21.3M.
  • Eversept Partners's ten largest holdings make up 51% of its $1.45B portfolio in Q3 2025.
  • Eversept Partners opened 31 new positions and closed 13 in Q3 2025.
  • Eversept Partners's portfolio value rose 33% quarter-over-quarter to $1.45B.

Based on Eversept Partners's 13F filing for Q3 2025, filed 14 Nov 2025.